Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alefacept: a safety profile.

Noah Scheinfeld1

  • 1Dept of Dermatology, St Lukes Hospital, NY, NY 10025, USA. NSS32@columbia.org

Expert Opinion on Drug Safety
|November 1, 2005
PubMed
Summary
This summary is machine-generated.

Alefacept is a safe biological therapy for psoriasis, effectively blocking T cell activation. Monitoring CD4 counts during 12-week treatment showed minimal utility, as side effects were minor and rare.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clostridium difficile arising in a patient with hidradenitis suppurativa on clindamycin and rifampin.

Dermatology online journal·2018
Same author

Squamous cell carcinoma of the cervix arising in a patient on adalimumab � a need for cervical screenings in patients on tumor necrosis factor inhibitors.

Dermatology online journal·2018
Same author

Amoxicillin-induced generalized eruption associated with Epstein-Barr virus reactivation in pregnancy.

International journal of dermatology·2017
Same author

Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system.

Dermatology online journal·2016
Same author

Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.

Dermatology online journal·2016
Same author

Apremilast (Otezla).

Skinmed·2016
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026
See all related articles

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Alefacept is an immunomodulating drug targeting T cell activation in psoriasis.
  • It selectively blocks the Lymphocyte Function-Associated Antigen-3 (LFA-3)/CD2 interaction.
  • This interaction is crucial for memory effector T cell activation and proliferation.

Purpose of the Study:

  • To evaluate the safety and efficacy of alefacept in treating moderate-to-severe chronic plaque psoriasis.
  • To assess the clinical utility of monitoring CD4+ T cell counts during alefacept therapy.

Main Methods:

  • Alefacept selectively binds to CD2 on T cells, inhibiting T cell activation.
  • Patients with moderate-to-severe chronic plaque psoriasis received alefacept treatment.
  • CD4+ T cell counts were monitored during the 12-week treatment period.

Related Experiment Videos

Main Results:

  • Alefacept demonstrated a favorable safety profile with few reported side effects compared to placebo.
  • Reported side effects were generally minor, including headache, upper respiratory infections, and fatigue.
  • Serious infections and malignancies were not linked to alefacept use.
  • The percentage of patients developing antibodies to alefacept was very low.
  • Monitoring CD4+ counts during the 12-week treatment showed minimal clinical utility.

Conclusions:

  • Alefacept is a safe and effective biological therapy for moderate-to-severe chronic plaque psoriasis.
  • The drug has a low incidence of side effects and does not appear to increase the risk of serious infections or malignancies.
  • Routine monitoring of CD4+ T cell counts during a 12-week course of alefacept therapy may not be necessary.